These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 25763933)

  • 1. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors from the natural origin: a recent perspective.
    Patel HM; Rane R; Thapliyal N; Palkar M; Shaikh M; Karpoormath R
    Anticancer Agents Med Chem; 2015; 15(8):988-1011. PubMed ID: 25763933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural Products Targeting EGFR Signaling Pathways as Potential Anticancer Drugs.
    Wang X; Xu L; Lao Y; Zhang H; Xu H
    Curr Protein Pept Sci; 2018 Feb; 19(4):380-388. PubMed ID: 28059040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of the Third Generation EGFR Tyrosine Kinase Inhibitors for Anticancer Therapy.
    Cheng W; Zhou J; Tian X; Zhang X
    Curr Med Chem; 2016; 23(29):3343-3359. PubMed ID: 27160532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insight into the medicinal chemistry of EGFR and HER-2 inhibitors.
    Wang C; Gao H; Dong J; Wang F; Li P; Zhang J
    Curr Med Chem; 2014; 21(11):1336-50. PubMed ID: 24251571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of quinoxalin-2(1H)-one derivatives as EGFR tyrosine kinase inhibitors.
    Qin X; Han X; Hu L; Li Z; Geng Z; Wang Z; Zeng C; Xiao X
    Anticancer Agents Med Chem; 2015; 15(2):267-73. PubMed ID: 25175686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy.
    Ayati A; Moghimi S; Salarinejad S; Safavi M; Pouramiri B; Foroumadi A
    Bioorg Chem; 2020 Jun; 99():103811. PubMed ID: 32278207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors.
    Milik SN; Lasheen DS; Serya RAT; Abouzid KAM
    Eur J Med Chem; 2017 Dec; 142():131-151. PubMed ID: 28754471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting epidermal growth factor receptor and its downstream signaling pathways by natural products: A mechanistic insight.
    Damare R; Engle K; Kumar G
    Phytother Res; 2024 May; 38(5):2406-2447. PubMed ID: 38433568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural Products as Chemopreventive Agents by Potential Inhibition of the Kinase Domain in ErbB Receptors.
    Olivero-Acosta M; Maldonado-Rojas W; Olivero-Verbel J
    Molecules; 2017 Feb; 22(2):. PubMed ID: 28218686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance.
    Fischer T; Najjar A; Totzke F; Schächtele C; Sippl W; Ritter C; Hilgeroth A
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1-8. PubMed ID: 29098884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein kinases as targets for developing anticancer agents from marine organisms.
    Qiao G; Bi K; Liu J; Cao S; Liu M; Pešić M; Lin X
    Biochim Biophys Acta Gen Subj; 2021 Jan; 1865(1):129759. PubMed ID: 33038451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors.
    Sabbah DA; Hajjo R; Sweidan K
    Curr Top Med Chem; 2020; 20(10):815-834. PubMed ID: 32124699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular modelling and synthesis of quinazoline-based compounds as potential antiproliferative agents.
    Yassen AS; Elshihawy HE; Said MM; Abouzid KA
    Chem Pharm Bull (Tokyo); 2014; 62(5):454-66. PubMed ID: 24789927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4-Anilinoquinazoline Derivatives with Epidermal Growth Factor Receptor Inhibitor Activity.
    Liu F; Tang B; Liu H; Li L; Liu G; Cheng Y; Xu Y; Chen W; Huang Y
    Anticancer Agents Med Chem; 2016; 16(12):1652-1664. PubMed ID: 27039919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting EGFR in pancreatic cancer treatment.
    Troiani T; Martinelli E; Capasso A; Morgillo F; Orditura M; De Vita F; Ciardiello F
    Curr Drug Targets; 2012 Jun; 13(6):802-10. PubMed ID: 22458527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
    Uribe P; Gonzalez S
    Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells.
    Berezowska S; Diermeier-Daucher S; Brockhoff G; Busch R; Duyster J; Grosu AL; Schlegel J
    Int J Mol Med; 2010 Nov; 26(5):713-21. PubMed ID: 20878094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural tyrosine kinase inhibitors acting on the epidermal growth factor receptor: Their relevance for cancer therapy.
    Liang Y; Zhang T; Zhang J
    Pharmacol Res; 2020 Nov; 161():105164. PubMed ID: 32846211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer.
    Mukherji D; Spicer J
    Expert Opin Investig Drugs; 2009 Mar; 18(3):293-301. PubMed ID: 19243280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.